Measuring transparency to improve good governance:
in the public pharmaceutical sector - Syrian Arab Republic
Access to medicines continues to be one of the biggest challenges for the Syrian Arab Republic. With total government health expenditure on medicines of around 45% in 2006, the pharmaceuticals sector is an attractive target for corruption.
Corruption manifests itself in different ways and works at different levels. For example, corrupt behaviour can emanate from information imbalances between the various stakeholders such as manufacturers, regulators, health care providers and consumers. When information is not shared equally and not all players have access to necessary information in order to be able to make independent assessments of medicines, or else processes are not clearly defined; vulnerability of the pharmaceutical sector to corruption increases. Corruption can have a significant impact on public health, the national economy and the credibility of institutions within public health sector.